Abcellera 宣布,其针对 Abcl635 的二期临床试验取得了积极的顶线数据。研究结果显示,该药物在降低血管舒缩症状的频率和严重程度方面表现出显著成效。同时,其良好的耐受性特征也一并得到证实。
Abcellera 宣布,其针对 Abcl635 的二期临床试验取得了积极的顶线数据。研究结果显示,该药物在降低血管舒缩症状的频率和严重程度方面表现出显著成效。同时,其良好的耐受性特征也一并得到证实。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.